PCI Biotech Holding ASA - Asset Resilience Ratio
PCI Biotech Holding ASA (PCIB) has an Asset Resilience Ratio of 73.51% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PCI Biotech Holding ASA (PCIB) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2024)
This chart shows how PCI Biotech Holding ASA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PCI Biotech Holding ASA total assets.
Liquid Assets Composition Over Time
This chart breaks down PCI Biotech Holding ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read PCIB total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr13.62 Million | 73.51% |
| Short-term Investments | Nkr0.00 | 0% |
| Total Liquid Assets | Nkr13.62 Million | 73.51% |
Asset Resilience Insights
- Very High Liquidity: PCI Biotech Holding ASA maintains exceptional liquid asset reserves at 73.51% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
PCI Biotech Holding ASA Industry Peers by Asset Resilience Ratio
Compare PCI Biotech Holding ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for PCI Biotech Holding ASA (2008–2024)
The table below shows the annual Asset Resilience Ratio data for PCI Biotech Holding ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 86.72% | Nkr27.07 Million ≈ $2.85 Million |
Nkr31.21 Million ≈ $3.28 Million |
-6.78pp |
| 2023-12-31 | 93.49% | Nkr41.18 Million ≈ $4.33 Million |
Nkr44.05 Million ≈ $4.64 Million |
+4.34pp |
| 2022-12-31 | 89.15% | Nkr56.60 Million ≈ $5.96 Million |
Nkr63.48 Million ≈ $6.68 Million |
+3.76pp |
| 2021-12-31 | 85.39% | Nkr116.12 Million ≈ $12.22 Million |
Nkr135.98 Million ≈ $14.31 Million |
-4.49pp |
| 2020-12-31 | 89.88% | Nkr187.97 Million ≈ $19.78 Million |
Nkr209.12 Million ≈ $22.01 Million |
-2.70pp |
| 2019-12-31 | 92.58% | Nkr261.10 Million ≈ $27.48 Million |
Nkr282.03 Million ≈ $29.68 Million |
-5.26pp |
| 2018-12-31 | 97.84% | Nkr349.33 Million ≈ $36.76 Million |
Nkr357.06 Million ≈ $37.57 Million |
+10.92pp |
| 2017-12-31 | 86.91% | Nkr50.79 Million ≈ $5.34 Million |
Nkr58.44 Million ≈ $6.15 Million |
+24.40pp |
| 2016-12-31 | 62.51% | Nkr14.00 Million ≈ $1.47 Million |
Nkr22.40 Million ≈ $2.36 Million |
+61.59pp |
| 2013-12-31 | 0.93% | Nkr489.00K ≈ $51.46K |
Nkr52.74 Million ≈ $5.55 Million |
+0.34pp |
| 2012-12-31 | 0.59% | Nkr463.00K ≈ $48.72K |
Nkr78.20 Million ≈ $8.23 Million |
+0.24pp |
| 2011-12-31 | 0.35% | Nkr351.00K ≈ $36.94K |
Nkr100.17 Million ≈ $10.54 Million |
-91.21pp |
| 2010-12-31 | 91.56% | Nkr104.88 Million ≈ $11.04 Million |
Nkr114.54 Million ≈ $12.05 Million |
+10.65pp |
| 2009-12-31 | 80.91% | Nkr33.60 Million ≈ $3.54 Million |
Nkr41.53 Million ≈ $4.37 Million |
-7.86pp |
| 2008-12-31 | 88.77% | Nkr48.45 Million ≈ $5.10 Million |
Nkr54.58 Million ≈ $5.74 Million |
-- |
About PCI Biotech Holding ASA
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vecto… Read more